Another study by Quartuccio et al. [67] hypothesized that overactivation of BAFF can be the reason for unsuccessful treatment with Rituximab in pSS patients, and our results showed that there is a positive correlation between LAMTOR4 and BAFF in the pSS SGs, indicating enrichment of mTOR signaling in the pSS SG. Here, LAMTOR4 is linked to peeling skin syndrome.